Forte Biosciences, Inc. (FBRX) 10-Year Financial Performance & Capital Metrics

FBRX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutForte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.Show more

Revenue $0
EBITDA -$37M -12.6%
Net Income -$35M -12.7%
EPS (Diluted) -12.17 +51.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -80.82% +4.8%
ROIC -102.45% +55.7%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 97 (top 3%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-51.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM77.94%

ROCE

10Y Avg-55.95%

5Y Avg-58.46%

3Y Avg-68.54%

Latest-83.38%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	51K	49K	41K	18.04M	0	0	0	0	0	0
Revenue Growth %	-	-0.04%	-0.16%	438.9%	-1%	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	11K	54K	36K	0	9K	39K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	51K	49K	41K	18.04M	-11K	-54K	-36K	0	-9K	-39K
Gross Margin %	1%	1%	1%	1%	-	-	-	-	-	-
Gross Profit Growth %	-	-0.04%	-0.16%	438.9%	-1%	-3.91%	0.33%	1%	-	-3.33%
Operating Expenses+	22.77M	31.48M	37.38M	63.26M	4.05M	14.17M	21.49M	13.9M	32.48M	36.56M
OpEx % of Revenue	446.53%	642.55%	911.66%	3.51%	-	-	-	-	-	-
Selling, General & Admin	3.6M	4.27M	8.27M	12.81M	1.38M	4.22M	7.63M	8.3M	10.62M	15.37M
SG&A % of Revenue	70.61%	87.08%	201.59%	0.71%	-	-	-	-	-	-
Research & Development	19.17M	27.22M	29.11M	50.45M	2.67M	9.95M	13.85M	5.59M	21.86M	21.19M
R&D % of Revenue	375.92%	555.47%	710.07%	2.8%	-	-	-	-	-	-
Other Operating Expenses	0	-50K	0	0	0	0	0	17K	0	0
Operating Income+	-22.95M	-31.69M	-37.63M	-45.85M	-4.06M	-14.22M	-21.49M	-13.9M	-32.49M	-36.6M
Operating Margin %	-450.08%	-646.76%	-917.78%	-2.54%	-	-	-	-	-	-
Operating Income Growth %	-	-0.38%	-0.19%	-0.22%	0.91%	-2.5%	-0.51%	0.35%	-1.34%	-0.13%
EBITDA+	-22.72M	-31.44M	-37.34M	-45.23M	-4.05M	-14.17M	-21.45M	-13.86M	-32.48M	-36.56M
EBITDA Margin %	-445.53%	-641.55%	-910.66%	-2.51%	-	-	-	-	-	-
EBITDA Growth %	-	-0.38%	-0.19%	-0.21%	0.91%	-2.5%	-0.51%	0.35%	-1.34%	-0.13%
D&A (Non-Cash Add-back)	232K	255K	292K	625K	11K	54K	36K	36K	9K	39K
EBIT	-22.72M	-31.43M	-37M	-44.32M	-4.07M	-46.49M	-21.49M	-13.9M	-32.49M	-35.48M
Net Interest Income+	0	0	1.9M	-173.38K	0	0	0	0	1.12M	1.31M
Interest Income	0	0	595K	0	0	0	0	0	1.12M	1.31M
Interest Expense	-102K	-1.84M	1.93M	173.38K	0	0	0	0	0	0
Other Income/Expense	-102K	-1.79M	-1.3M	-1.4M	-5K	-32.26M	-222K	17K	1.01M	1.12M
Pretax Income+	-23.06M	-33.48M	-38.93M	-47.26M	-4.07M	-46.49M	-21.71M	-13.88M	-31.48M	-35.48M
Pretax Margin %	-452.08%	-683.22%	-949.49%	-2.62%	-	-	-	-	-	-
Income Tax+	-204K	0	0	1.7M	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1.04%	1%	1%	1%	1%	1%	1%
Net Income+	-23.06M	-33.48M	-38.93M	-48.95M	-4.07M	-46.49M	-21.71M	-13.86M	-31.48M	-35.48M
Net Margin %	-452.08%	-683.22%	-949.49%	-2.71%	-	-	-	-	-	-
Net Income Growth %	-	-0.45%	-0.16%	-0.26%	0.92%	-10.42%	0.53%	0.36%	-1.27%	-0.13%
Net Income (Continuing)	-23.06M	-33.48M	-38.93M	-48.95M	-4.07M	-46.49M	-21.71M	-13.88M	-31.48M	-35.48M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-474.15	-634.80	-997.50	-915.18	-48.25	-157.93	-38.85	-19.96	-24.92	-12.17
EPS Growth %	-	-0.34%	-0.57%	0.08%	0.95%	-2.27%	0.75%	0.49%	-0.25%	0.51%
EPS (Basic)	-474.15	-634.80	-997.50	-915.18	-48.25	-157.93	-38.85	-19.96	-24.92	-12.17
Diluted Shares Outstanding	48.63K	52.74K	38.95K	53.49K	84.33K	294.36K	558.71K	695.34K	1.26M	2.92M
Basic Shares Outstanding	48.63K	52.74K	38.95K	53.49K	84.33K	294.36K	558.71K	695.34K	1.26M	2.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	60.2M	32.46M	90.63M	97.75M	7.51M	59.9M	42.52M	41.51M	38.33M	61.35M
Cash & Short-Term Investments	58.91M	31.25M	88.72M	96.09M	6.94M	58.77M	42.04M	41.1M	37.13M	58.37M
Cash Only	8.15M	5.51M	35.93M	40.81M	6.94M	58.77M	42.04M	41.1M	11.96M	22.24M
Short-Term Investments	50.76M	25.73M	52.79M	55.27M	0	0	0	0	25.16M	36.12M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.29M	1.22M	1.9M	1.66M	3K	76K	89K	70K	165K	336K
Total Non-Current Assets+	1.97M	2.89M	1.44M	5.33M	152K	1.34M	786K	486K	653K	215K
Property, Plant & Equipment	445K	743K	1.22M	3.97M	152K	97K	0	0	109K	77K
Fixed Asset Turnover	0.11x	0.07x	0.03x	4.54x	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.52M	2.15M	227K	1.36M	0	1.24M	786K	486K	544K	138K
Total Assets+	62.17M	35.35M	92.07M	103.08M	7.66M	61.24M	43.31M	42M	38.98M	61.56M
Asset Turnover	0.00x	0.00x	0.00x	0.17x	-	-	-	-	-	-
Asset Growth %	-	-0.43%	1.6%	0.12%	-0.93%	7%	-0.29%	-0.03%	-0.07%	0.58%
Total Current Liabilities+	5.93M	14.38M	17.33M	16.53M	1.91M	2.26M	1.76M	3.18M	3.67M	9.08M
Accounts Payable	1.3M	1.67M	1.95M	78.38K	1.57M	1.24M	946K	1.15M	1.42M	4.88M
Days Payables Outstanding	-	-	-	-	52.06K	8.38K	9.59K	-	57.75K	45.66K
Short-Term Debt	600K	7.2M	7.2M	0	0	0	0	0	0	0
Deferred Revenue (Current)	145K	79K	59K	36K	0	0	0	0	0	0
Other Current Liabilities	3.37M	4.71M	8.12M	10.25M	168K	0	0	890K	947K	1.55M
Current Ratio	10.14x	2.26x	5.23x	5.91x	3.93x	26.52x	24.19x	13.06x	10.45x	6.76x
Quick Ratio	10.14x	2.26x	5.23x	5.91x	3.93x	26.52x	24.19x	13.06x	10.45x	6.76x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17.16M	13.97M	3.66M	28.4M	0	0	0	0	0	0
Long-Term Debt	16.87M	13.78M	3.63M	26.2M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	-36K	0	0	0	0	0	0	0
Other Non-Current Liabilities	176K	126K	0	2.2M	0	0	0	0	0	0
Total Liabilities	23.09M	28.36M	20.99M	44.94M	1.91M	2.26M	1.76M	3.18M	3.67M	9.08M
Total Debt+	17.47M	20.98M	10.82M	26.2M	0	0	0	0	0	0
Net Debt	9.32M	15.47M	-25.11M	-14.61M	-6.94M	-58.77M	-42.04M	-41.1M	-11.96M	-22.24M
Debt / Equity	0.45x	3.00x	0.15x	0.45x	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-19.48x	-264.47x	-	-	-	-	-	-
Total Equity+	39.08M	7M	71.08M	58.15M	5.75M	58.98M	41.55M	38.82M	35.31M	52.48M
Equity Growth %	-	-0.82%	9.16%	-0.18%	-0.9%	9.26%	-0.3%	-0.07%	-0.09%	0.49%
Book Value per Share	803.75	132.66	1824.81	1086.98	68.14	200.37	74.36	55.83	27.96	18.00
Total Shareholders' Equity	39.08M	7M	71.08M	58.15M	5.75M	58.98M	41.55M	38.82M	35.31M	52.48M
Common Stock	2K	2K	20K	23K	2K	13K	15K	21K	36K	6K
Retained Earnings	-94.51M	-128M	-166.93M	-215.88M	-4.97M	-51.46M	-73.17M	-87.04M	-118.52M	-154M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-58K	-2.41M	-34K	-23K	0	-61.24M	-43.31M	0	4K	11K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-21.04M	-29.54M	-31.13M	-34.47M	-2.77M	-18.42M	-16.68M	-8.19M	-28.71M	-30.75M
Operating CF Margin %	-412.59%	-602.84%	-759.34%	-1.91%	-	-	-	-	-	-
Operating CF Growth %	-	-0.4%	-0.05%	-0.11%	0.92%	-5.65%	0.09%	0.51%	-2.51%	-0.07%
Net Income	-23.06M	-33.48M	-38.93M	-48.95M	-4.07M	-46.49M	-21.71M	-13.88M	-31.48M	-35.48M
Depreciation & Amortization	232K	255K	292K	625K	11K	54K	36K	0	9K	39K
Stock-Based Compensation	0	0	4.45M	6.87M	0	956K	0	4.01M	3.28M	3.1M
Deferred Taxes	0	0	-4.45M	-6.87M	0	0	0	0	0	0
Other Non-Cash Items	928K	1.74M	5.26M	7.77M	36K	30.89M	4.28M	0	-131K	-158K
Working Capital Changes	747K	1.87M	2.52M	6.08M	1.25M	-3.83M	720K	1.68M	-392K	1.76M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	571K	586K	304K	1.26M	976K	-369K	-294K	207K	271K	3.02M
Cash from Investing+	-24.93M	24.57M	-27.71M	-4.19M	-162K	3.58M	0	0	47K	-35.99M
Capital Expenditures	-231K	-525K	-655K	-1.97M	-162K	0	0	0	-88K	-37K
CapEx % of Revenue	4.53%	10.71%	15.98%	0.11%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-24.7M	25.09M	-27.05M	-2.22M	0	3.58M	0	0	0	0
Cash from Financing+	49.92M	2.33M	89.26M	43.54M	4.86M	66.67M	-44K	7.24M	24.68M	51.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-982K	-592K	0	-8.63M	0	-32K	-106K	12K	-44K	-1.14M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.27M	-30.06M	-31.79M	-36.44M	-2.93M	-18.42M	-16.68M	-8.19M	-28.79M	-30.78M
FCF Margin %	-417.12%	-613.55%	-775.32%	-2.02%	-	-	-	-	-	-
FCF Growth %	-	-0.41%	-0.06%	-0.15%	0.92%	-5.28%	0.09%	0.51%	-2.52%	-0.07%
FCF per Share	-437.48	-570.06	-816.06	-681.17	-34.78	-62.59	-29.85	-11.77	-22.80	-10.56
FCF Conversion (FCF/Net Income)	0.91x	0.88x	0.80x	0.70x	0.68x	0.40x	0.77x	0.59x	0.91x	0.87x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-58.99%	-145.31%	-99.72%	-75.77%	-12.74%	-143.64%	-43.19%	-34.5%	-84.92%	-80.82%
Return on Invested Capital (ROIC)	-35.56%	-67.07%	-82.47%	-76.84%	-14.4%	-	-	-	-231.26%	-102.45%
Gross Margin	100%	100%	100%	100%	-	-	-	-	-	-
Net Margin	-45207.84%	-68322.45%	-94948.78%	-271.43%	-	-	-	-	-	-
Debt / Equity	0.45x	3.00x	0.15x	0.45x	-	-	-	-	-	-
Interest Coverage	-	-	-19.48x	-264.47x	-	-	-	-	-	-
FCF Conversion	0.91x	0.88x	0.80x	0.70x	0.68x	0.40x	0.77x	0.59x	0.91x	0.87x
Revenue Growth	-	-3.92%	-16.33%	43890.24%	-100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Forte Biosciences, Inc. (FBRX) grew revenue by 0.0% over the past year. Growth has been modest.

Forte Biosciences, Inc. (FBRX) reported a net loss of $51.7M for fiscal year 2024.

Dividend & Returns

Forte Biosciences, Inc. (FBRX) has a return on equity (ROE) of -80.8%. Negative ROE indicates the company is unprofitable.

Forte Biosciences, Inc. (FBRX) had negative free cash flow of $44.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Forte Biosciences, Inc. (FBRX) 10-Year Financial Performance & Capital Metrics

FBRX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$37M -12.6%
Net Income -$35M -12.7%
EPS (Diluted) -12.17 +51.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -80.82% +4.8%
ROIC -102.45% +55.7%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 97 (top 3%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-51.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM77.94%

ROCE

10Y Avg-55.95%

5Y Avg-58.46%

3Y Avg-68.54%

Latest-83.38%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	51K	49K	41K	18.04M	0	0	0	0	0	0
Revenue Growth %	-	-0.04%	-0.16%	438.9%	-1%	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	11K	54K	36K	0	9K	39K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	51K	49K	41K	18.04M	-11K	-54K	-36K	0	-9K	-39K
Gross Margin %	1%	1%	1%	1%	-	-	-	-	-	-
Gross Profit Growth %	-	-0.04%	-0.16%	438.9%	-1%	-3.91%	0.33%	1%	-	-3.33%
Operating Expenses+	22.77M	31.48M	37.38M	63.26M	4.05M	14.17M	21.49M	13.9M	32.48M	36.56M
OpEx % of Revenue	446.53%	642.55%	911.66%	3.51%	-	-	-	-	-	-
Selling, General & Admin	3.6M	4.27M	8.27M	12.81M	1.38M	4.22M	7.63M	8.3M	10.62M	15.37M
SG&A % of Revenue	70.61%	87.08%	201.59%	0.71%	-	-	-	-	-	-
Research & Development	19.17M	27.22M	29.11M	50.45M	2.67M	9.95M	13.85M	5.59M	21.86M	21.19M
R&D % of Revenue	375.92%	555.47%	710.07%	2.8%	-	-	-	-	-	-
Other Operating Expenses	0	-50K	0	0	0	0	0	17K	0	0
Operating Income+	-22.95M	-31.69M	-37.63M	-45.85M	-4.06M	-14.22M	-21.49M	-13.9M	-32.49M	-36.6M
Operating Margin %	-450.08%	-646.76%	-917.78%	-2.54%	-	-	-	-	-	-
Operating Income Growth %	-	-0.38%	-0.19%	-0.22%	0.91%	-2.5%	-0.51%	0.35%	-1.34%	-0.13%
EBITDA+	-22.72M	-31.44M	-37.34M	-45.23M	-4.05M	-14.17M	-21.45M	-13.86M	-32.48M	-36.56M
EBITDA Margin %	-445.53%	-641.55%	-910.66%	-2.51%	-	-	-	-	-	-
EBITDA Growth %	-	-0.38%	-0.19%	-0.21%	0.91%	-2.5%	-0.51%	0.35%	-1.34%	-0.13%
D&A (Non-Cash Add-back)	232K	255K	292K	625K	11K	54K	36K	36K	9K	39K
EBIT	-22.72M	-31.43M	-37M	-44.32M	-4.07M	-46.49M	-21.49M	-13.9M	-32.49M	-35.48M
Net Interest Income+	0	0	1.9M	-173.38K	0	0	0	0	1.12M	1.31M
Interest Income	0	0	595K	0	0	0	0	0	1.12M	1.31M
Interest Expense	-102K	-1.84M	1.93M	173.38K	0	0	0	0	0	0
Other Income/Expense	-102K	-1.79M	-1.3M	-1.4M	-5K	-32.26M	-222K	17K	1.01M	1.12M
Pretax Income+	-23.06M	-33.48M	-38.93M	-47.26M	-4.07M	-46.49M	-21.71M	-13.88M	-31.48M	-35.48M
Pretax Margin %	-452.08%	-683.22%	-949.49%	-2.62%	-	-	-	-	-	-
Income Tax+	-204K	0	0	1.7M	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1.04%	1%	1%	1%	1%	1%	1%
Net Income+	-23.06M	-33.48M	-38.93M	-48.95M	-4.07M	-46.49M	-21.71M	-13.86M	-31.48M	-35.48M
Net Margin %	-452.08%	-683.22%	-949.49%	-2.71%	-	-	-	-	-	-
Net Income Growth %	-	-0.45%	-0.16%	-0.26%	0.92%	-10.42%	0.53%	0.36%	-1.27%	-0.13%
Net Income (Continuing)	-23.06M	-33.48M	-38.93M	-48.95M	-4.07M	-46.49M	-21.71M	-13.88M	-31.48M	-35.48M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-474.15	-634.80	-997.50	-915.18	-48.25	-157.93	-38.85	-19.96	-24.92	-12.17
EPS Growth %	-	-0.34%	-0.57%	0.08%	0.95%	-2.27%	0.75%	0.49%	-0.25%	0.51%
EPS (Basic)	-474.15	-634.80	-997.50	-915.18	-48.25	-157.93	-38.85	-19.96	-24.92	-12.17
Diluted Shares Outstanding	48.63K	52.74K	38.95K	53.49K	84.33K	294.36K	558.71K	695.34K	1.26M	2.92M
Basic Shares Outstanding	48.63K	52.74K	38.95K	53.49K	84.33K	294.36K	558.71K	695.34K	1.26M	2.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	60.2M	32.46M	90.63M	97.75M	7.51M	59.9M	42.52M	41.51M	38.33M	61.35M
Cash & Short-Term Investments	58.91M	31.25M	88.72M	96.09M	6.94M	58.77M	42.04M	41.1M	37.13M	58.37M
Cash Only	8.15M	5.51M	35.93M	40.81M	6.94M	58.77M	42.04M	41.1M	11.96M	22.24M
Short-Term Investments	50.76M	25.73M	52.79M	55.27M	0	0	0	0	25.16M	36.12M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.29M	1.22M	1.9M	1.66M	3K	76K	89K	70K	165K	336K
Total Non-Current Assets+	1.97M	2.89M	1.44M	5.33M	152K	1.34M	786K	486K	653K	215K
Property, Plant & Equipment	445K	743K	1.22M	3.97M	152K	97K	0	0	109K	77K
Fixed Asset Turnover	0.11x	0.07x	0.03x	4.54x	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.52M	2.15M	227K	1.36M	0	1.24M	786K	486K	544K	138K
Total Assets+	62.17M	35.35M	92.07M	103.08M	7.66M	61.24M	43.31M	42M	38.98M	61.56M
Asset Turnover	0.00x	0.00x	0.00x	0.17x	-	-	-	-	-	-
Asset Growth %	-	-0.43%	1.6%	0.12%	-0.93%	7%	-0.29%	-0.03%	-0.07%	0.58%
Total Current Liabilities+	5.93M	14.38M	17.33M	16.53M	1.91M	2.26M	1.76M	3.18M	3.67M	9.08M
Accounts Payable	1.3M	1.67M	1.95M	78.38K	1.57M	1.24M	946K	1.15M	1.42M	4.88M
Days Payables Outstanding	-	-	-	-	52.06K	8.38K	9.59K	-	57.75K	45.66K
Short-Term Debt	600K	7.2M	7.2M	0	0	0	0	0	0	0
Deferred Revenue (Current)	145K	79K	59K	36K	0	0	0	0	0	0
Other Current Liabilities	3.37M	4.71M	8.12M	10.25M	168K	0	0	890K	947K	1.55M
Current Ratio	10.14x	2.26x	5.23x	5.91x	3.93x	26.52x	24.19x	13.06x	10.45x	6.76x
Quick Ratio	10.14x	2.26x	5.23x	5.91x	3.93x	26.52x	24.19x	13.06x	10.45x	6.76x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17.16M	13.97M	3.66M	28.4M	0	0	0	0	0	0
Long-Term Debt	16.87M	13.78M	3.63M	26.2M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	-36K	0	0	0	0	0	0	0
Other Non-Current Liabilities	176K	126K	0	2.2M	0	0	0	0	0	0
Total Liabilities	23.09M	28.36M	20.99M	44.94M	1.91M	2.26M	1.76M	3.18M	3.67M	9.08M
Total Debt+	17.47M	20.98M	10.82M	26.2M	0	0	0	0	0	0
Net Debt	9.32M	15.47M	-25.11M	-14.61M	-6.94M	-58.77M	-42.04M	-41.1M	-11.96M	-22.24M
Debt / Equity	0.45x	3.00x	0.15x	0.45x	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-19.48x	-264.47x	-	-	-	-	-	-
Total Equity+	39.08M	7M	71.08M	58.15M	5.75M	58.98M	41.55M	38.82M	35.31M	52.48M
Equity Growth %	-	-0.82%	9.16%	-0.18%	-0.9%	9.26%	-0.3%	-0.07%	-0.09%	0.49%
Book Value per Share	803.75	132.66	1824.81	1086.98	68.14	200.37	74.36	55.83	27.96	18.00
Total Shareholders' Equity	39.08M	7M	71.08M	58.15M	5.75M	58.98M	41.55M	38.82M	35.31M	52.48M
Common Stock	2K	2K	20K	23K	2K	13K	15K	21K	36K	6K
Retained Earnings	-94.51M	-128M	-166.93M	-215.88M	-4.97M	-51.46M	-73.17M	-87.04M	-118.52M	-154M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-58K	-2.41M	-34K	-23K	0	-61.24M	-43.31M	0	4K	11K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-21.04M	-29.54M	-31.13M	-34.47M	-2.77M	-18.42M	-16.68M	-8.19M	-28.71M	-30.75M
Operating CF Margin %	-412.59%	-602.84%	-759.34%	-1.91%	-	-	-	-	-	-
Operating CF Growth %	-	-0.4%	-0.05%	-0.11%	0.92%	-5.65%	0.09%	0.51%	-2.51%	-0.07%
Net Income	-23.06M	-33.48M	-38.93M	-48.95M	-4.07M	-46.49M	-21.71M	-13.88M	-31.48M	-35.48M
Depreciation & Amortization	232K	255K	292K	625K	11K	54K	36K	0	9K	39K
Stock-Based Compensation	0	0	4.45M	6.87M	0	956K	0	4.01M	3.28M	3.1M
Deferred Taxes	0	0	-4.45M	-6.87M	0	0	0	0	0	0
Other Non-Cash Items	928K	1.74M	5.26M	7.77M	36K	30.89M	4.28M	0	-131K	-158K
Working Capital Changes	747K	1.87M	2.52M	6.08M	1.25M	-3.83M	720K	1.68M	-392K	1.76M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	571K	586K	304K	1.26M	976K	-369K	-294K	207K	271K	3.02M
Cash from Investing+	-24.93M	24.57M	-27.71M	-4.19M	-162K	3.58M	0	0	47K	-35.99M
Capital Expenditures	-231K	-525K	-655K	-1.97M	-162K	0	0	0	-88K	-37K
CapEx % of Revenue	4.53%	10.71%	15.98%	0.11%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-24.7M	25.09M	-27.05M	-2.22M	0	3.58M	0	0	0	0
Cash from Financing+	49.92M	2.33M	89.26M	43.54M	4.86M	66.67M	-44K	7.24M	24.68M	51.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-982K	-592K	0	-8.63M	0	-32K	-106K	12K	-44K	-1.14M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.27M	-30.06M	-31.79M	-36.44M	-2.93M	-18.42M	-16.68M	-8.19M	-28.79M	-30.78M
FCF Margin %	-417.12%	-613.55%	-775.32%	-2.02%	-	-	-	-	-	-
FCF Growth %	-	-0.41%	-0.06%	-0.15%	0.92%	-5.28%	0.09%	0.51%	-2.52%	-0.07%
FCF per Share	-437.48	-570.06	-816.06	-681.17	-34.78	-62.59	-29.85	-11.77	-22.80	-10.56
FCF Conversion (FCF/Net Income)	0.91x	0.88x	0.80x	0.70x	0.68x	0.40x	0.77x	0.59x	0.91x	0.87x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-58.99%	-145.31%	-99.72%	-75.77%	-12.74%	-143.64%	-43.19%	-34.5%	-84.92%	-80.82%
Return on Invested Capital (ROIC)	-35.56%	-67.07%	-82.47%	-76.84%	-14.4%	-	-	-	-231.26%	-102.45%
Gross Margin	100%	100%	100%	100%	-	-	-	-	-	-
Net Margin	-45207.84%	-68322.45%	-94948.78%	-271.43%	-	-	-	-	-	-
Debt / Equity	0.45x	3.00x	0.15x	0.45x	-	-	-	-	-	-
Interest Coverage	-	-	-19.48x	-264.47x	-	-	-	-	-	-
FCF Conversion	0.91x	0.88x	0.80x	0.70x	0.68x	0.40x	0.77x	0.59x	0.91x	0.87x
Revenue Growth	-	-3.92%	-16.33%	43890.24%	-100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Forte Biosciences, Inc. (FBRX) grew revenue by 0.0% over the past year. Growth has been modest.

Forte Biosciences, Inc. (FBRX) reported a net loss of $51.7M for fiscal year 2024.

Dividend & Returns

Forte Biosciences, Inc. (FBRX) has a return on equity (ROE) of -80.8%. Negative ROE indicates the company is unprofitable.

Forte Biosciences, Inc. (FBRX) had negative free cash flow of $44.6M in fiscal year 2024, likely due to heavy capital investments.